ProtoKinetix

ProtoKinetix Market capitalization

The The market capitalization of ProtoKinetix (PKTX) as of Nov 19, 2026 is 3.21 M USD. In the previous year, The market capitalization was 3.21 M USD — a change of 0.00% (lower).

Market capitalization

3.21 MUSD

YoY

0.00%

Last updated:

In 2025, ProtoKinetix's market cap stood at 3.21 M USD, a 0.00% increase from the 3.21 M USD market cap in the previous year.

The ProtoKinetix Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2018
3.21 M USD
Jan 1, 2019
3.21 M USD
Jan 1, 2020
3.21 M USD
Jan 1, 2021
3.21 M USD
Jan 1, 2022
3.21 M USD
Jan 1, 2023
3.21 M USD
Jan 1, 2024
3.21 M USD
Jan 1, 2025
3.21 M USD
The ProtoKinetix Market capitalization history
YEARMarket capitalizationYoY
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD0.00%
3.21 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring ProtoKinetix's Market Capitalization

ProtoKinetix's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of ProtoKinetix's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

ProtoKinetix's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in ProtoKinetix’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about ProtoKinetix stock

The market capitalization of ProtoKinetix is 3.21 M USD in 2025.

The market capitalization of ProtoKinetix changed from 3.21 M USD to 3.21 M USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's ProtoKinetix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ProtoKinetix

All Key Metrics — ProtoKinetix